Table 3.
Effectiveness, safety, and tolerability profiles of carbapenems in the selected studies.
| First Author | Sputum Smear Conversion (%) | Sputum Culture Conversion (%) | Treatment Success (%) ** | Adverse events Attributed to Carbapenems (%) | Interruption of Carbapenems Due to Adverse Events (%) |
|---|---|---|---|---|---|
| Chambers H.F. [33] | ND | 7/9 (77.8) | 7/10 (70.0) | ND | ND |
| Palmero D. [40] | ND | 8/10 (80.0) | 3/6 (50.0) | 0/10 (0.0) | ND |
| De Lorenzo S. [29] | 28/32 (87.5) | 31/37 (83.8) | ND | 5/37 (13.5) | 2/5 (40.0) |
| van Rijn S.P. [32] | ND | 15/18 (83.3) | 15/18 (83.3) | 2/18 (11.1) | 3/18 (16.7) |
| Tiberi S. [31] | 3/5 (60.0) | 3/5 (60.0) | 4/5 (80.0) | 0/5 (0.0) | 2/5 (40.0) |
| Tiberi S. [41] | 55/58 (94.8) | 55/58 (94.8) | 55/96 (57.3) | 6/93 (6.5) | 8/94 (8.5) |
| Payen M.C. [30] | 5/6 (83.3) | 5/6 (83.3) | ND | 0/6 (0.0) | 0/6 (0.0) |
| Tiberi S. [42] | 51/64 (79.7) | 46/64 (71.9) | 34/57 (59.7) | 3/56 (5.4) | 4/55 (7.3) |
| Tiberi S. [43] * | Imipenem 51/64 (79.7) Meropenem 55/58 (94.8) | Imipenem 46/64 (71.9) Meropenem 55/58 (94.8) | Imipenem 34/57 (59.7) Meropenem 55/71 (77.5) | Imipenem 3/56 (5.4) Meropenem 6/93 (6.5) | Imipenem 4/55 (7.3) Meropenem 8/94 (8.5) |